Cibus, Inc. Announces Pricing of Public Offering of Class A Common Stock

Rhea-AI Summary

Cibus (Nasdaq: CBUS) priced an underwritten offering of 6,976,744 Class A shares at $2.15 per share on March 26, 2026, with a 30-day underwriter option for an additional 1,046,511 shares.

Gross proceeds are approximately $15.0 million (or $17.2 million if the option is exercised). The offering is expected to close March 27, 2026. Net proceeds are intended for working capital and to fund development of weed management traits in rice.

Positive

• Gross proceeds of approximately $15.0M
• Proceeds designated to fund weed management traits in rice
• Underwriter option increases potential proceeds to $17.2M

Negative

• Issuance of 6,976,744 new shares may dilute existing shareholders
• Offering price of $2.15 could create near-term selling pressure

News Market Reaction – CBUS

-25.78% 2.2x vol

35 alerts

-25.78% Session close to close

-26.9% Trough in 30 hr 42 min

$198.59M Market Cap

2.2x Rel. Volume

In the Mar 26 session, CBUS declined 25.78%, reflecting a significant negative market reaction. Argus tracked a trough of -26.9% from its starting point during tracking. Our momentum scanner triggered 35 alerts that day, indicating elevated trading interest and price volatility. Trading volume was elevated at 2.2x the daily average, suggesting increased selling activity.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -25.8% in the session following this news. A negative reaction despite the capital...

Analysis

The stock dropped -25.8% in the session following this news. A negative reaction despite the capital raise would fit the broader pattern in which offering news often weighed on CBUS, with an average move of -10.21% across 5 prior offering-related events and single-day drops as steep as -34.32%. History shows that dilution concerns and going-concern risk from recent filings have driven volatility. If selling intensified, it would be consistent with past skepticism toward repeated equity financings for the Rice trait program.

Key Figures

Primary shares offered: 6,976,744 shares Offering price: $2.15 per share Over-allotment option: 1,046,511 shares +5 more

8 metrics

Primary shares offered 6,976,744 shares Underwritten public offering of Class A Common Stock

Offering price $2.15 per share Purchase price for Class A Common Stock in the offering

Over-allotment option 1,046,511 shares 30-day option for underwriter to buy additional shares

Gross proceeds $15 million Estimated gross proceeds without over-allotment

Gross proceeds (with option) $17.2 million If underwriter exercises 30-day option in full

Expected closing date March 27, 2026 Anticipated closing of the offering

Shelf file number File No. 333-273062 Form S-3 registration statement referenced for this offering

Pre-news share price $2.87 Last price, up 5.9% over prior day

Previous Offering Reports

5 past events · Latest: Jan 29 (Negative)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jan 29	Offering pricing	Negative	+9.1%	Priced $20M underwritten offering at $1.50 with board participation.
Jan 28	Offering proposed	Negative	+9.1%	Announced proposed offering under Form S-3 for working capital and Rice traits.
Jun 09	Offering closing	Negative	-0.6%	Closed $27.5M offering at $1.75; proceeds for Rice traits and working capital.
Jun 05	Offering pricing	Negative	-34.3%	Priced $27.5M common stock offering at $1.75 per share.
Jun 04	Offering proposed	Negative	-34.3%	Proposed equity offering to fund Rice traits and working capital.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Equity offerings have produced mixed reactions: some sharp selloffs but also notable positive moves around certain financings.

Recent Company History

Over the last year, Cibus has repeatedly used equity offerings to fund development of its Rice weed‑management traits and working capital. Prior deals on Jun 4–9, 2025 and Jan 28–29, 2026 were all conducted under an effective registration statement, with varying investor responses. Some pricing/proposed offering announcements saw steep declines, while others around $20.0M raises coincided with gains. Today’s offering continues this pattern of financing tied to the Rice trait pipeline.

Key Terms

underwritten public offering, over-allotments, gross proceeds, shelf registration statement, +3 more

7 terms

underwritten public offering financial

"announced the pricing of an underwritten public offering (the “Offering”) of 6,976,744"

An underwritten public offering is when a company sells new shares of its stock to the public with the help of a financial firm, called an underwriter. The underwriter agrees to buy all the shares upfront, reducing the company's risk, and then sells them to investors. This process helps companies raise money quickly and confidently from a wide range of buyers.

over-allotments financial

"option to purchase up to an additional 1,046,511 shares of Class A Common Stock to cover over-allotments"

An over-allotment is a temporary extra batch of shares that the underwriters of a stock offering are allowed to sell beyond the original amount, with the right to buy those shares back later. Think of it as spare tickets sold to meet demand and then reclaimed if needed to keep the market orderly; it helps stabilize the stock price after an offering and can affect short-term supply and potential dilution, which matters to investors tracking price and ownership stakes.

gross proceeds financial

"The gross proceeds of the Offering will be approximately $15 million"

The total amount of cash a company receives from a financing event or sale before any fees, expenses, taxes or deductions are taken out. Investors watch gross proceeds because it shows the raw scale of new capital being raised—think of it as the paycheck amount before withholdings—which helps assess how much funding is available for operations, growth, debt payoff or how much shareholder dilution might occur once costs are removed.

shelf registration statement regulatory

"This Offering is being made pursuant to an effective shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement describing the terms of the Offering will be filed with the SEC"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

base prospectus regulatory

"Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained"

A base prospectus is a detailed document that provides essential information about a financial offering, such as a bond or share issue. It acts like a comprehensive guide for investors, explaining what the investment involves, the risks involved, and how the process works. This helps investors make informed decisions before committing their money.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced the pricing of an underwritten public offering (the “Offering”) of 6,976,744 shares of its Class A Common Stock, par value $0.0001 per share (“Class A Common Stock”) at a purchase price of $2.15 per share of Class A Common Stock.

The Company has also granted the underwriter a 30-day option to purchase up to an additional 1,046,511 shares of Class A Common Stock to cover over-allotments, if any. All shares of Class A Common Stock to be sold in the Offering are to be sold by the Company.

The gross proceeds of the Offering will be approximately $15 million (or $17.2 million if the underwriter exercises its option to purchase additional shares of Class A Common Stock in full) before deducting underwriting discounts and commissions in the Offering and other estimated expenses payable by the Company. The Offering is expected to close on March 27, 2026, subject to the satisfaction of customary closing conditions. The Company currently intends to use the net proceeds from the Offering for working capital and general corporate purposes, including to fund further development of its weed management traits in Rice.

BTIG, LLC is acting as the sole underwriter for the Offering.

This Offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-273062), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 30, 2023, as amended on October 25, 2023, and declared effective by the SEC on October 27, 2023. A prospectus supplement describing the terms of the Offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the prospectus supplement and the accompanying base prospectus, when available, may be obtained from BTIG, LLC, at 65 East 55th Street, New York, New York 10022 or by telephone at (212) 593-7555, or by email at ProspectusDelivery@btig.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Cibus

Cibus is a leader in developing traits (characteristics) that address critical productivity, yield and sustainability challenges. Cibus’ proprietary high-throughput gene editing technologies drive its long-term focus on productivity traits for farmers for the major global row crops. Cibus is not a seed company. It is a technology company that uses its gene editing technologies to develop plant traits at a fraction of the time and cost of conventional breeding and to license them to customers in exchange for royalties.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. In some cases, you can identify these statements by forward-looking words such as “anticipates,” “believes,” “continue,” “estimates,” “expects,” “intends,” “may,” “might,” “plans,” “predicts,” “projects,” “should,” “targets,” “will,” or the negative of these terms and other similar terminology. Forward-looking statements in this press release include, but are not limited to, statements regarding the anticipated closing of the Offering and the expected use of the proceeds from the Offering. Completion of the Offering is subject to numerous factors, many of which are beyond Cibus’ control, including, without limitation, market conditions, failure to satisfy customary closing conditions and the risk factors and other matters set forth in the prospectus supplement and accompanying prospectus included in the registration statement and the documents incorporated by reference therein. You are cautioned not to place undue reliance on any forward-looking statements made by Cibus’ management, which are based only on information currently available to it when, and speak only as of the date, such statement is made. Cibus does not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

CIBUS CONTACTS:

INVESTOR RELATIONS
Jeff Sonnek – ICR
jeff.sonnek@icrinc.com

MEDIA RELATIONS
media@cibus.com

Colin Sanford
colin@bioscribe.com
203-918-4347

FAQ

How many shares did Cibus (CBUS) offer and at what price on March 26, 2026?

Cibus offered 6,976,744 Class A shares at $2.15 per share. According to the company, the offering also includes a 30-day underwriter option to purchase up to 1,046,511 additional shares to cover over-allotments.

What are the expected proceeds and closing date for the CBUS public offering?

The offering is expected to generate roughly $15.0 million before fees and close on March 27, 2026. According to the company, proceeds could reach $17.2 million if the underwriter exercises its full option.

How does Cibus (CBUS) plan to use the net proceeds from the March 2026 offering?

Cibus intends to use net proceeds for working capital and general corporate purposes. According to the company, funds will specifically help fund further development of its weed management traits in rice.

Who is underwriting the Cibus (CBUS) March 2026 offering and where is the prospectus filed?

BTIG, LLC is the sole underwriter for the offering. According to the company, the offering is made under an effective Form S-3 shelf and a prospectus supplement will be filed with the SEC and available on its website.

Will the Cibus (CBUS) offering increase if the underwriter exercises its option?

Yes. If the underwriter exercises its 30-day option in full, the company could sell an additional 1,046,511 shares, increasing gross proceeds to approximately $17.2 million, according to the company.